Moreover, there are registered clinical studies in phase I and phase II using STING agonists, such as SNX281, TAK-500 and IMSA101 in patients with solid tumors or lymphomas (ClinicalTrials.gov identifiers: NCT04609579; NCT05070247; NCT05846659). Here, STING1 is linked to lymphoma.